Thus, AngII-regulated enhancers/SEs, and their associated lncRNAs could represent novel targets for the development of better drugs for hypertension, atherosclerosis, and renal diseases, especially for patients who do not respond well to currently available AngII receptor blockers and ACE inhibitors4. The gene discussed is ACE; the disease is kidney disorder.